SEC Form 4 · accession 0001104659-16-128424
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur S Kirsch
Director
Period of report
Jun 16, 2016
Accepted (ET)
Jun 20, 2016 · 9:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | Jun 16, 2016 | A | 7,500 | $0.00 | A | 104,109 | D | |
| Common Shares, without par valueF3 | holding | — | — | — | 5,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $3.42 | Jun 16, 2016 | A | 15,000 | A | — | Jun 16, 2026 | Common Shares, without par value | 15,000 | 15,000 | D |
Explanation of responses
- F1Restricted Stock Units, all of which vest on the earlier of June 16, 2017 or the date of the Company's next annual shareholder meeting, subject to the director's continued service on the Board as of such date.
- F2Includes 96,609 shares of Common Stock and 7,500 Restricted Stock Units.
- F3The shares are held by the Laura A. Kirsch Trust, dated 4/12/2000 (the "Trust"), of which the Reporting Person is a trustee. Pursuant to General Instruction 4(b)(iv) to Form 4, all of the Issuer's securities held by the Trust are reported herein, and the Reporting Person expressly disclaims beneficial ownership of the securities held by the Trust, except to the extent of his pecuniary interest therein.
- F4The option vests in one installment on the earlier of June 16, 2017 or the date of the Company's next annual shareholder meeting, subject to the director's continued service on the Board as of such date.